Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine
NCT05811923 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2023-04-13
Summary
The purpose of this study is to evaluate the acute impact of ingesting individual and combined dosages of caffeine and paraxanthine in comparison to placebo on changes in resting metabolic rate, perceived levels of affect, and markers of lipolysis.
Conditions
- Metabolic Syndrome
- Caffeine
Interventions
- OTHER
-
Venous Blood Collection
Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
- OTHER
-
Resting Metabolic Rate Determination
During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
- OTHER
-
Mood State
Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
- OTHER
-
Visual Analog Scales
Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by "Lowest Possible" and "Highest Possible" to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020).
Sponsors & Collaborators
-
Lindenwood University
lead OTHER
Principal Investigators
-
Chad M Kerksick, PhD · Lindenwood University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 39 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-12-12
- Primary Completion
- 2022-10-12
- Completion
- 2022-10-12
Countries
- United States
Study Locations
More Related Trials
-
Effects of Herbal Products on Metabolism and Hunger
NCT00198952 ·Status: COMPLETED ·Phase: NA
-
Do Antidepressants Induce Metabolic Syndromes METADAP Study
NCT00526383 ·Status: COMPLETED ·Phase: NA
-
Effect of mCPP on Cognitive Control, Appetite, and Neural Responses
NCT03962829 ·Status: TERMINATED ·Phase: NA
-
Dopamine Action on Metabolism in Relation to Genotype
NCT03525002 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
NCT00677313 ·Status: COMPLETED ·Phase: NA
-
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
NCT02069379 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Metabolic State on Anxiety in Human Subjects
NCT01322243 ·Status: TERMINATED ·Phase: NA
-
Brain Dopamine Function in Human Obesity
NCT03648892 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation
NCT00287053 ·Status: COMPLETED ·Phase: PHASE4
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
NCT03364803 ·Status: RECRUITING
-
Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids
NCT03023891 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
NCT02708394 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934 ·Status: COMPLETED ·Phase: NA
-
Heart Rate Variability in Response to Metformin Challenge
NCT02500628 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
NCT00809536 ·Status: TERMINATED ·Phase: PHASE1
-
A New Supplement for the "Metabolic Syndrome"
NCT03813914 ·Status: COMPLETED ·Phase: NA
-
Bromocriptine and Insulin Sensitivity
NCT02428946 ·Status: COMPLETED ·Phase: NA
-
The Effect of 5-Hydroxytryptophan (5-HTP) on Satiety
NCT00328913 ·Status: COMPLETED ·Phase: PHASE2
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine
NCT06147622 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacoepigenetics of Bipolar Disorder Treatment
NCT02374996 ·Status: COMPLETED
-
Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage
NCT01783717 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
NCT00339014 ·Status: COMPLETED ·Phase: PHASE2
-
Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis
NCT01939093 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
NCT01071044 ·Status: COMPLETED ·Phase: PHASE4